AC Immune SA (ACIU) Covered Calls

You can sell covered calls on AC Immune SA to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for ACIU (prices last updated Fri 4:16 PM ET):

AC Immune SA (ACIU) Stock Quote
Last	Change	Bid	Ask	Volume	P/E	Market Cap
3.19	-0.36	3.16	3.38	234K	-	0.3

Covered Calls For AC Immune SA (ACIU)
Expiration	Strike	Call Bid	Net Debit	Return If Flat	Annualized Return If Flat
Dec 20	2.5	0.00	3.38	-26.0%	-263.6%
Jan 17	2.5	0.00	3.38	-26.0%	-148.3%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls? Sign Up For A Free Trial

Extended Business Description

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company's lead product candidate is crenezumab, a humanized, monoclonal, and conformation-specific anti-Abeta antibody, which is in Phase II clinical prevention trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as is in Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that has completed Phase Ib clinical study; RG6100, an anti-Tau antibody candidate, which is in Phase II clinical study for AD patients; and Tau-PET imaging tracer that has completed Phase I clinical study. In addition, the company is researching and developing Tau Morphomer aggregation inhibitor small molecules for AD. Further, it has discovery and pre-clinical stage molecules targeting neurodegenerative diseases, as well as diagnostics targeting Tau, alpha-synuclein, and TDP-43 aggregates. The company has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; Essex Bio-Technology Limited; and WuXi Biologics. It also has a research collaboration with University of Pennsylvania to focus on pathogenic protein TDP-43 in neurodegenerative diseases. AC Immune SA was founded in 2003 and is headquartered in Lausanne, Switzerland.

Top 10 Open Interest For Dec 20 Expiration				Top 5 High Yield
1.	NVDA covered calls	6.	QQQ covered calls	1.	SAVA covered calls
2.	SPY covered calls	7.	XLF covered calls	2.	RKLB covered calls
3.	EEM covered calls	8.	KWEB covered calls	3.	LUNR covered calls
4.	FXI covered calls	9.	TLT covered calls	4.	NMRA covered calls
5.	IWM covered calls	10.	KRE covered calls	5.	CRVS covered calls

Want more examples? ACI Covered Calls | ACIW Covered Calls